Selective inhibition of neurogenic, but not agonist‐induced contractions by phospholipase A2 inhibitors points to presynaptic phospholipase A2 functions in contractile neurotransmission to human prostate smooth muscle

Abstract

AbstractBackgroundPhospholipases A2 (PLA2) may be involved in α1‐adrenergic contraction by formation of thromboxane A2 in different smooth muscle types. However, whether this mechanism occurs with α1‐adrenergic contractions of the prostate, is still unknown. While α1‐adrenoceptor antagonists are the first line option for medical treatment of voiding symptoms in benign prostatic hyperplasia (BPH), improvements are limited, probably by nonadrenergic contractions including thromboxane A2. Here, we examined effects of PLA2 inhibitors on contractions of human prostate tissues.MethodsProstate tissues were obtained from radical prostatectomy. Contractions were induced by electric field stimulation (EFS) and by α1‐adrenergic agonists in an organ bath, after application of the cytosolic PLA2 inhibitors ASB14780 and AACOCF3, the secretory PLA2 inhibitor YM26734, the leukotriene receptor antagonist montelukast, or of solvent to controls.ResultsFrequency‐dependent contractions of human prostate tissues induced by EFS were inhibited by 25% at 8 Hz, 38% at 16 Hz and 37% at 32 Hz by ASB14780 (1 µM), and by 32% at 16 Hz and 22% at 32 Hz by AACOCF3 (10 µM). None of both inhibitors affected contractions induced by noradrenaline, phenylephrine or methoxamine. YM26734 (3 µM) and montelukast (0.3 and 1 µM) neither affected EFS‐induced contractions, nor contractions by α1‐adrenergic agonists, while all contractions were substantially inhibited by silodosin (100 nM).ConclusionsOur findings suggest presynaptic PLA2 functions in prostate smooth muscle contraction, while contractions induced by α1‐adrenergic agonists occur PLA2‐independent. Lacking sensitivity to montelukast excludes an involvement of PLA2‐derived leukotrienes in promotion of contractile neurotransmission.